Insulin Therapy in Type 2 Diabetes: Indications & Regimens

Insulin is not a treatment failure but a physiological necessity when β-cell function declines below the threshold to maintain glycemic targets. Modern guidelines position it flexibly.

ADA/EASD 2023 Indications for Insulin Initiation

  • Symptomatic hyperglycemia / catabolism (weight loss, polyuria, ketosis) at any HbA1c.
  • HbA1c >10% (86 mmol/mol) or >9% (75 mmol/mol) with symptoms – start insulin ± GLP-1 RA immediately.
  • HbA1c >9% after 3 months on dual/triple oral therapy (metformin + 1–2 agents).
  • Inability to use non-insulin agents (CKD, GI intolerance, contraindications, cost/access).
  • Special situations: Pregnancy (GDM/T2D), perioperative, glucocorticoid therapy, hospitalization.
  • Patient preference after informed discussion.

Common Initiation Regimens

RegimenStarting DoseTitrationBest For
Basal Only (Glargine U100/U300, Degludec, Detemir)10 U or 0.1–0.2 U/kg↑2–4 U every 3–7 days to FPG target (80–130 mg/dL)Most T2D; simple, low hypoglycemia, weight neutral
Basal + 1 Rapid (Basal-Bolus)Basal as above + 4 U or 10% basal at largest mealAdjust per meal PPG target (<180 mg/dL)High postprandial excursions, erratic schedule
Premixed (70/30, 75/25)0.3–0.5 U/kg divided BIDAdjust per pre-meal glucoseRegular meals, limited titration ability, cost
GLP-1 RA + Basal Insulin (Fixed Ratio)iGlarLixi (LixiLan), IDegLira (Xultophy)Per product algorithmSynergy; ↓weight, ↓hypo vs insulin alone

Key Principles

  • Continue metformin + SGLT2i/GLP-1 RA (cardiorenal benefits, ↓insulin dose/weight).
  • Hypoglycemia prevention: Education, CGM, glucagon, liberalize targets if high risk (elderly, CKD, CVD, hypoglycemia unawareness).
  • Weight management: Insulin causes ~2–4 kg gain; mitigate with GLP-1 RA/SGLT2i, diet, activity.
  • CGM is standard of care for all on insulin (ADA 2023).

Barriers & Solutions

  • Fear of injections → pens, short needles (4–5 mm), demo.
  • Hypoglycemia fear → education, CGM, newer analogs (degludec, glargine U300).
  • Cost → biosimilars, patient assistance, older insulins (NPH/Regular) if needed.
  • Stigma → reframe as hormone replacement.

Insulin therapy is individualized, dynamic, and collaborative. Early initiation when indicated prevents glucotoxicity and preserves β-cells.

Diabetes - Related Articles